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Summary 26 
Three dendrimeric peptides were synthesized in order to evaluate their immunogenicity 27 
and their potential protection against classical swine fever virus (CSFV) in domestic pigs. 28 
Construct 1, an optimized version of a previously used dendrimer, had four copies of a 29 
B-cell epitope derived from CSFV E2 glycoprotein connected to an also CSFV-derived 30 
T-cell epitope through maleimide instead of thioether linkages. Construct 2 was similarly 31 
built but included only two copies of the B-cell epitope, and in also bivalent construct 3 32 
the CSFV T-cell epitope was replaced by a previously described one from the 3A protein 33 
of foot-and-mouth disease virus (FMDV). Animals were inoculated twice with a 21-day 34 
interval and challenged 15 days after the second immunization. Clinical signs were 35 
recorded daily and ELISA tests were performed to detect antibodies against specific 36 
peptide and E2. The neutralising antibody response was assessed 13 days after challenge. 37 
Despite the change to maleimide connectivity, only partial protection against CSFV was 38 
again observed. The best clinical protection was observed in group 3. Animals inoculated 39 
with constructs 2 and 3 showed higher anti-peptide humoral response, suggesting that two 40 
copies of the B-cell epitope are sufficient or even better than four copies for swine 41 
immune recognition. In addition, for construct 3 higher neutralizing antibody titres 42 
against CSFV were detected. Our results support the immunogenicity of the CSFV B-cell 43 
epitope and the cooperative role of the FMDV 3A T-cell epitope in inducing a neutralising 44 
response against CSFV in domestic pigs. This is also the first time that the FMDV T-cell 45 
epitope shows effectivity in improving swine immune response against a different virus. 46 
Our findings highlight the relevance of dendrimeric peptides as a powerful tool for 47 
epitope characterization and antiviral strategies development.   48 
 49 
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Classical swine fever (CSF) is a highly contagious disease causing huge economic losses 56 
to the pig industry worldwide. Its etiological agent, classical swine fever virus (CSFV), 57 
is a member of the Pestivirus genus within the Flaviviridae family (Simmonds et al., 58 
2012). The disease remains endemic in Central and South America, Eastern Europe and 59 
some regions of Asia, where vaccination with live attenuated vaccines is routinely used, 60 
even though such vaccines do not allow the differentiation of vaccinated from infected 61 
animals (DIVA concept) (Coronado et al., 2017). It is known that the epidemiological 62 
situation generated by CSFV in endemic countries is quite complex in spite of the 63 
extensive vaccination programs. Thus, the need for a vaccine that can induce an effective 64 
immune response and meets DIVA criteria has become a major goal of CSFV research 65 
(Blome et al., 2017; Ganges et al., 2008). In such context, identification of epitopes 66 
providing enhanced cellular and humoral immune responses is crucial in the development 67 
of both potent DIVA vaccines and diagnostic tools essential for CSFV control. 68 
A well recognised strategy to improve the immunogenicity of peptide antigens is to 69 
present them in a clustered dendrimeric (branched) format first introduced by Tam (Tam 70 
et al., 2002) as multiple antigenic peptide (MAP) systems. The MAP design is based on 71 
a branched oligolysine core to which various copies of the peptide antigen are attached. 72 
MAP-based constructs are effective as candidate vaccines, as well as for identification of 73 
new viral epitopes and basic virus-host interactions research (reviewed in (Heegaard et 74 
al., 2010)).  75 
Previous work in some of our laboratories has shown the ability of dendrimeric peptide 76 
constructs to provide solid protection against foot-and-mouth disease virus (FMDV) in 77 
domestic pigs (Cubillos et al., 2012, 2008). FMDV is a picornavirus that produces a 78 
highly transmissible and devastating disease of farm animals, mostly cattle and swine 79 
(Blanco et al., 2016). 80 
 The original prototype (Cubillos et al., 2008) was a MAP-like construct [B4T(thi)] 81 
containing four copies of a B-cell epitope [residues (136-154) of viral protein VP1] linked 82 
through thioether bonds to a T-cell epitope identified in residues (21-35) of non-structural 83 
protein 3A of FMDV shown to significantly improve the immune response against 84 
FMDV in domestic pigs (Cubillos et al., 2012). Recently, a structurally simplified version 85 
of that B4T(thi) prototype, bearing only two copies of the B-cell epitope and using 86 
thioether [B2T(thi)] or maleimide [B2T(mal)] linkages to the T-cell epitope sequence, 87 
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elicited similar or higher B and T-cell specific responses in swine than the earlier 88 
tetravalent version (Blanco et al., 2016). 89 
For CSFV several peptide vaccine strategies have been previously described, although 90 
full protection was not achieved in any of these studies. Thus, the peptide vaccine strategy 91 
is still in an experimental stage (revised in Blome et al., 2017). By using dendrimeric 92 
peptides, a B4T(thi)-type platforms with a B-cell epitope from E2 (residues 694–712) and 93 
a T-cell epitope from NS3 (residues 1446–1460) has been described (Monsó et al., 2011; 94 
Tarradas et al., 2012, 2011). Despite affording only partial protection, the strategy has 95 
allowed characterizing the NS3 peptide as a potent T-helper sequence, capable of 96 
enhancing the specific humoral response in domestic pigs, and also proven the usefulness 97 
of branched constructs as diagnostic tools (Tarradas et al., 2012).    98 
Against this background, we have investigated the immune response elicited by three new 99 
versions of the branched constructs (Table 1). One of the constructs (1) is tetravalent, of 100 
the B4T(mal)-type, while the other two (2, 3) are bivalent, B2T(mal)-type, differing only 101 
in the T-cell epitope: in 2, the aforementioned NS3 sequence is used, as in 1, whereas in 102 
3 the [3A(21-35)] T-cell epitope successfully used in FMDV vaccines has been adopted. 103 
Given the advantageous performance –both immunological and synthetic– of the 104 
maleimide linkage, this connectivity has been chosen in all cases. The constructs have 105 
been evaluated in pigs, with a view to compare how bivalent 2 and/or 3 perform relative 106 
to tetravalent 1 in terms of CSFV specific responses.  107 
Peptides 1-3 were made by thiol-maleimide ligation of pre-purified precursors prepared 108 
by solid phase synthesis, as described in detail elsewhere (Blanco et al., 2016; Monsó et 109 
al., 2013). The B-cell epitope moiety had an additional C-terminal Cys, while the T-cell 110 
epitope sequence was N-terminally elongated with two Lys units followed by either one 111 
[B2T(mal)-type] or three [B2T(mal)-type] extra Lys residues in a branched arrangement 112 
(see Table 1 for details). All peptides were purified by preparative reverse phase HPLC 113 
to near homogeneity (>95% by analytical HPLC) and characterized for identity by 114 
MALDI-TOF mass spectrometry.  115 
A total of sixteen domestic pigs (Landrace x Large white, 6 week old; numbered 1-16) 116 
distributed in four groups of four animals each were used. Animals 1-4 (group 1), 5-8 117 
(group 2) and 9-12 (group 3), were immunized with dendrimeric constructs 1-3, 118 
respectively. Two doses of 2 mg each of the corresponding construct, dissolved in 1 mL 119 
of NaCl 0.9% solution and mixed with 1 mL of Montanide v206 adjuvant (Seppic), were 120 
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administered at days 1 and 21 of the experiment by intramuscular (i.m.) injection in the 121 
neck region. Four additional pigs (13-16, group 4) were also i.m. inoculated with saline 122 
solution plus adjuvant as negative controls. Fifteen days after the second immunization 123 
(day 36), pigs were challenged with 105 TCID50 of CSFV (Margarita strain) by i.m. 124 
injection in the neck (Tarradas et al., 2012, 2011). Animals remained infected during 125 
fifteen days post CSFV challenge (end of the trial) in the BSL3 animal facility at CReSA 126 
(Barcelona, Spain). A peroxidase-linked assay (PLA) (Wensvoort et al., 1986) was used 127 
for viral titration following the statistical method described by (Reed and Muench, 1938). 128 
The rectal temperatures and clinical signs were recorded daily by a trained veterinarian 129 
in a blinded manner. The clinical status of the animals was scored from 0 to 6 as reported 130 
for this viral strain (Tarradas et al., 2014). Animals with a clinical score value of 5 or 131 
higher or showing prostration behaviour were euthanized for ethical reasons, The 132 
experiments were approved by the Ethics Committee for Animal Experiments of the 133 
Universitat Autònoma de Barcelona (UAB) according to existing national and European 134 
regulations.  135 
Dendrimeric peptide-specific antibodies in pig sera were tested by means of construct-136 
specific ELISAs. Specific anti-peptide IgG was detected at 1,7,14, 21 and 36 days post 137 
vaccination (dpv) as well as at the day of CSFV challenge, 5, 8 and 13 days post challenge 138 
(dpc), as described (Tarradas et al., 2012, 2011). In all cases, sera from control animals 139 
were included as negative controls. Cut-off value was set at 0.5 O.D. Serum samples were 140 
also analysed using a CSFV-specific E2 ELISA (HerdChek CSFV Ab, IDEXX) following 141 
the manufacturer’s recommendations. Serum samples collected at 13 dpc were also tested 142 
by the neutralisation peroxidase-linked assay (NPLA) (Terpstra et al., 1984). For CSFV 143 
RNA detection, RNA was extracted from serum and rectal swabs using the viral RNA 144 
isolation kit Nucleospin II according to the manufacturer's instructions (Macherey-145 
Nagel). The presence of CSFV RNA in sera was analysed by real time (RT)-PCR 146 
(Hoffmann et al., 2005). Positive results were considered for threshold cycle values (CT) 147 
equal or less than 42.  148 
Statistical analyses was performed using SPSS 15.0 software (SPSS Inc., Chicago, IL, 149 
USA). For all the analyses, the pig was used as the experimental unit. The significance 150 
level (p) was set at 0.05, with statistical tendencies being reported when p < 0.10. A non-151 
parametric test (Wilcoxon) was chosen to compare the clinical parameters and anti-152 
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peptide antibody response between groups throughout the trial. This non-parametric 153 
analysis was applied due to the non-normality pattern observed for this parameter and the 154 
small number of animals used in each experimental group. 155 
Three of the four pigs immunized with construct 3 showed a potent and early (14 dpv) 156 
antibody response against the peptide used for immunization as determined by 157 
dendrimeric peptide-specific ELISA. This response increased in all animals after the 158 
second immunisation (day of viral challenge) (Figure 1). Three of the four pigs 159 
immunized with construct 2 showed peptide-specific antibodies at 21 dpv and at 36 dpv. 160 
Finally, the lowest anti-peptide antibody response was found in pigs immunized with 161 
construct 1, which showed a detectable response only after boost immunisation (day of 162 
challenge) that was maintained until the end of the experiment at 15 dpc. As expected, 163 
control animals did not show specific anti-peptide antibodies against any of the 164 
dendrimers analysed. Thus, construct 3 evoked the quicker and higher anti-peptide 165 
humoral response among the dendrimers analysed with statistical significant difference 166 
(p=0.03) from the day of viral challenge (at 36 dpv) until 8 dpc. 167 
Regarding the protection conferred by these dendrimers upon viral challenge, control 168 
animals developed pyrexia (rectal temperature above 40 °C), which appeared between 4 169 
and 5 dpc. From 7 dpc these pigs also developed severe clinical signs related with CSFV 170 
and all were euthanized between 11 and 13 dpc with the highest clinical score values (> 171 
4 points). In contrast, animals from the three vaccinated groups showed delayed onset of 172 
CSFV, moderate to severe clinical signs (>3 points in score value). One pig from each 173 
immunized group had to be euthanized before the end of the trial, at 11 dpc (groups 2 and 174 
3) and at 13 dpc (group 1). However, all immunized groups exhibited statistically 175 
significant lower clinical scores than those of the control pigs (p<0.05) during the first 10 176 
dpc (Figure 2). Animals inoculated with peptide 3 showed statistical difference with the 177 
control group from day 6 to 10 dpc, whereas the other groups showed statistical difference 178 
from day 6 to 9 dpc (group 1) and at days 6 and 10 dpc (group 2). Furthermore, the mean 179 
clinical score value was lower for group 3 towards the end of the study (Figure 2). 180 
Control animals failed to develop detectable anti E2 antibodies by the commercial ELISA 181 
(HerdChek CSFV Ab, IDEXX). In contrast, four out of the twelve peptide immunized 182 
animals developed a specific E2 antibody response at 13 dpc, two pigs from group 1 and 183 
the other two from groups 2 and 3, (even this latter having an FMDV epitope), 184 
respectively. As previous studies, neutralising antibody response to CSFV after 185 
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dendrimeric peptide immunization with titres over 1:32 was found only at 13 dpc 186 
(Tarradas et al., 2012);  in one animal from group 1 (1:40) and two pigs from group 3, 187 
(1:160 and 1:40, respectively).  188 
CSFV RNA was detectable by qRT-PCR in serum samples from all pigs at 5 dpc with a 189 
mean Ct value of 29 in the four experimental groups. At 13 dpc, the Ct values ranged 190 
from 22.31 to 24.01 (group 1), 19.86 to 25.39 (group 2) and 23.12 to 28.63 (group 3) in 191 
immunized-challenged pigs (Table 2). 192 
Despite the change in the conjugation method between B- and T-cell peptides from 193 
thioether to maleimide, tetravalent construct 1 conferred levels of protection similar to 194 
those described for peptide [B4T(thi)] (Monsó et al., 2011; Tarradas et al., 2011). 195 
Interestingly, animals inoculated with constructs 2 and 3 showed a higher anti-peptide 196 
humoral response than animals from group 1. Contructs 2 and 3 comprise only two copies 197 
of the B cell epitope, suggesting that bivalence is advantageous for dendrimer recognition 198 
by the swine immune system, as reported for FMDV analogous constructs (Blanco et al., 199 
2016, 2013). Despite the anti-peptide antibody response elicited by the CSFV 200 
dendrimeric constructs was unable to confer complete protection against CSFV,  our 201 
results support that bivalent dendrimers, in particular construct 3, evoke faster and higher 202 
antibody responses that the tetravalent construct 1 (Figure 1).  203 
On the other hand, higher neutralizing antibody titres (>1:32) at 13 dpc, which have been 204 
previously related with CSFV protection (Terpstra and Wensvoort, 1988), were elicited 205 
by construct 3 immunized pigs at 13 dpc. This response combined with the reduction and 206 
delayed onset of moderate-severe CSFV clinical signs; supports the role of the CSFV B-207 
cell epitope in the E2 glycoprotein (694–712). Likewise, suggests the cooperative 208 
capacity of the FMDV 3A [3A (21-35)] T cell epitope in the induction of an effective 209 
neutralising antibody response against CSFV in domestic pigs. These findings correlate 210 
with previous studies which suggests that the FMDV 3A T cell epitope may facilitate the 211 
antigen presentation and generate a boost effect against FMDV in the swine immune 212 
system (Blanco et al., 2016; Cubillos et al., 2012). In this regard, it is worth mentioning 213 
that the FMDV 3A T cell epitope included into the construct 3 fails to detect FMDV 214 
specific antibodies in infected swine. Thus, the use of this epitope would not generate 215 
cross-reactions in the serological response of FMDV. Considering that, our results 216 
provide valuable information in the development of new CSFV diagnostic strategies. 217 
Further optimization of dendrimeric construct 3, could generate a more potent protection 218 
against CSFV. These findings highlight the relevance in the use of dendrimeric peptides 219 
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for epitope characterization as powerful tools in the development of antiviral strategies  220 
in animal health. 221 
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Figure legends 306 
 307 
Figure 1. Anti-peptide antibody response detected by dendrimeric peptide-specific 308 
ELISA in animals inoculated with construct 1 (A), construct 2 (B) and construct 309 
3 (C). Black bars represent inoculated animals at different time post immunization 310 
and viral challenge. In the graphic, 0 dpc corresponds with the day of CSFV 311 
challenge.  Animals not shown at 8 and 13 dpc were euthanized before day of 312 
sampling. * Symbol indicates a euthanized pig after sampling. Construct 3 elicited 313 
higher anti-peptide humoral response among the dendrimers analysed with 314 
statistical significant difference (p<0.05) from the day of viral challenge until 8 315 
dpc. 316 
 317 
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Figure 2. Mean clinical score per group after CSFV challenge. Symbol *, indicates 318 
statistical difference between control group and all peptide-inoculated groups 319 
(p<0.05). Symbol ±, indicates statistical difference between control group and 320 
groups 1 and 3 (p<0.05). Symbol #, indicates statistical difference between control 321 
group and group 3 (p<0.05). One pig from each immunized group had to be 322 
euthanized before the end of the trial, at 11 dpc (groups 2 and 3) and at 13 dpc 323 
(group 1) 324 
 325 
 326 
 327 
 328 
Table 1. Dendrimeric peptides used in this study 329 
Construct Type General structurea B-cell epitope  T-cell epitope  
1 B4T(mal) 
 E2 glycoprotein of CSFV, 
residues 694-712: 
KEDFRYAISSTNEIGLLGA 
Non-structural NS3  
protein of CSFV, 
residues 1446-1460: 
KHKVRNEVMVHWFGD 
 
2 
B2T(mal) 
 
3 B2T(mal) 
Non-structural protein  
3A of FMDV,  
residues 21–35: 
AAIEFFEGMVHDSIK 
a In all constructs, the C-terminal Cys thiol group is linked to the Lys core via a 3-330 
maleimidopropionic acid unit ( =         ) 331 
 332 
B epitope
Lys-Lys-Lys- T epitope
Lys
Lys
B epitope
B epitope
B epitope
B epitope
Lys-Lys-Lys-
B epitope
T epitope
12 
 
Table 2. Detection of CSFV RNA for real time RT-PCR in serum samples collected after 333 
CSFV challenge (13 dpc).  334 
 335 
 336 
 337 
 338 
 339 
 340 
 341 
 342 
 343 
 344 
 345 
 346 
 347 
                    348 
 349 
                                  * Pig euthanized after sample collection  350 
  351 
Group Animal Ct value  
Mean Ct value 
per group 
 
Construct 1 
 
1 24.01  
2 22.31 23.92 
3 26.15  
4* 23.23  
 
Construct 2 
 
5 19.86  
6 22.91 22.72 
8 25.39  
 
Construct 3 
 
9 28.63  
10 23.12 25.34 
12 24.27  
Control  16 22.99 22.99 
